#drugdevelopment--HTuO Biosciences, a biotechnology company developing an innovative molecular simulation platform for drug discovery, announces it has joined Johnson & Johnson Innovation - JLABS ...
HTuO Biosciences, a computational drug discovery biotechnology company, is pleased to announce joining Johnson & Johnson Innovation – JLABS
VANCOUVER, British Columbia: #drugdevelopment--HTuO Biosciences, a biotechnology company developing an innovative molecular simulation platform for drug discovery, announces it has joined Johnson & Johnson Innovation - JLABS as a resident virtual company.
HTuO Biosciences aims to revolutionize drug design and optimization with AtomForge, a platform powered by a proprietary physics engine and machine learning. AtomForge will redefine molecular modelling, drug discovery, and approaches to targeting undruggable proteins.
Dr. Anthony Fejes, CEO and co-founder of HTuO Biosciences, remarks:
“We are thrilled to join JLABS as it will provide world-class mentorship, industry connections and research capabilities. Becoming a JLABS member is a testament to our technology, the team, and the strength of the biotechnology sector in British Columbia.”
HTuO Biosciences is a virtual company of Johnson & Johnson Innovation - JLABS, a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps pharmaceutical, medical technology, and health tech entrepreneurs bring healthcare solutions to patients and consumers. More information: http://jlabs.jnjinnovation.com/
About HTuO
HTuO Biosciences is a computational biotechnology company based in Vancouver, Canada, with the mission of developing advanced molecular simulation software capable of accurately predicting the behaviour of molecules to accelerate drug optimization and expand the range of druggable targets. The core technology, the AtomForge force field, is powered by a novel physics algorithm and utilizes a machine learning approach to go beyond the limits of current computer-aided drug design tools. To learn more, please visit www.htuobio.com.
Fonte: Business Wire
The Italian company partners with MainStreaming for high-performance, energy-efficient video streaming
Software vendors developing vertical solutions against specific attack vectors are 'cool' again. And when it comes to email security, all companies now…
Links Management and Technology just concluded the testing phase of a research project focused on banking transformation
Axyon AI offers an AI platform specifically designed for asset management, with several interesting strengths for those approaching machine/deep learning…
The "Switzerland Existing & Upcoming Data Center Portfolio" database has been added to ResearchAndMarkets.com's offering. This database product covers…
Jenna Wells, former Marine Corps Captain and Chief Customer & Product Officer of real-time risk intelligence platform Supply Wisdom, is available…
Intelligent power management company Eaton (NYSE:ETN) today announced that Tiffany Hanisch has been named senior vice president, Internal Audit, effective…
Transact Campus, (“Transact”) the award winning leader in innovative mobile credential and payment solutions for a connected campus, today announced the…